PDCD1 and non-small cell lung carcinoma: The immune checkpoint pathway has been shown to play a crucial role in mediating immune tolerance in NSCLC, with antibody agents that block this pathway (e.g., agents against PD1/PD-L1) producing durable responses14,15, and where expression of checkpoint markers correlates with treatment efficacy5.